ArticleFrontiers in pharmacology2024

Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.

Kejia Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.